Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries

Size: px
Start display at page:

Download "Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries"

Transcription

1 Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries FUJIFILM Holdings Corporation Chairman and Chief Executive Officer Shigetaka Komori December 15, 2016

2 Key Business Areas Expanding Business in Six Priority Areas Healthcare Graphic Systems Digital Imaging Highly Functional Key Materials Business Areas Document Solutions Optical Devices 1

3 Overview of Wako Pure Chemical Industries, Ltd. Company Name: Incorporation: 1922 Business Overview: Revenue: Wako Pure Chemical Industries, Ltd. Chemicals Department of Takeda Pharmaceutical separated and established as Takeda Pure Chemical Ltd. Manufacturing and sales of laboratory chemicals, clinical diagnostic reagents and speciality chemicals JPY 79.4 billion (FY2016/3, Consolidated) Clinical Diagnostic Reagents JPY 26.0bn Laboratory Chemicals JPY 36.6bn Speciality Chemicals JPY 16.7bn 2

4 Objectives and Purposes of Acquisition Graphic Systems Digital Imaging Healthcare Clinical Diagnostic Reagents Key Business Areas Laboratory Chemicals Highly Functional Materials Speciality Chemicals Optical Devices Document Solutions 3

5 Objectives and Purposes of Acquisition Technology fusion of Fujifilm and Wako Healthcare Advancement of medical applications in regenerative medicines Improvement quality of medical care through widespread use of In-Vitro Diagnostics Industrial Contribution to advancement of cutting edge technology in semiconductor industry Creating innovation with development of new highly functional materials Stable supply of high quality pharmaceuticals through expansion of contract manufacturing Addressing Social Challenges 4

6 The Acquisition of Wako Pure Chemical Industries FUJIFILM Holdings Corporation President and Chief Operation Officer Kenji Sukeno December 15, 2016

7 Business Overview of Wako Pure Chemical Laboratory Chemicals related to: Cell culture medium DNA/Protein research Analysis of environment/food area Organic synthesis, etc. Clinical Diagnostics Reagents Revenue: JPY36.6bn (46% of total) For automated bio chemical analyzer, etc. For immune system and microorganism, etc. Speciality Chemicals Revenue: JPY26.0bn (33% of total) Revenue: JPY16.7bn (21% of total) Semiconductor Materials (detergent for post CMP process, etc.) Azo polymerization initiator for superabsorbent polymer Pharmaceutical intermediate, etc. Clinical Diagnostics Reagents Laboratory Chemicals Specialty Chemicals 6

8 Expected Synergies through the Acquisition Expanding Healthcare Business 1) Regenerative Medicine 2) In-Vitro Diagnostics 3) Pharmaceutical Contract Development and Manufacturing Organization(CDMO) Expanding Highly Functional Materials Business 1) Electronic Materials 2) Industrial Products 7

9 The Three Key Components for Regenerative Medicine Cell Scaffold (recombinant peptide) Cell Culture Medium Cytokine Fujifilm group to own all three key components for regenerative medicine 8

10 Regenerative Medicine Business Scaffold (recombinant peptide) Patent & Know-how for Cell Production and Cultivation 画像診断技術 Development/ Manufacturing of ips Cell Development/ Manufacturing of Regenerative Medicine Products Cell Culture Medium Manufacturing Technology GMP Certified Manufacturing Facilities Dispersion/Synthesis Technology Expanding Regenerative Medicine Business 9

11 In-Vitro Diagnosis (Medical System Business) Clinical Chemical Analysis System Immunodiagnosis System Global Business Platform through Medical Devices < 和光純薬 > 免疫分析装置 System 生化学分析試薬国内の営業網 Immune Analysis Laboratory Chemicals for Biochemical Analysis Extensive Sales Network with Access to Clinical Facilities in Japan Promoting In-Vitro Diagnostic Products Developing high-functional In-Vitro Diagnostic Products 10

12 Pharmaceutical CDMO (Pharmaceutical Business) Chemical Synthesis Technology of Small Molecule Drugs FUJIFILM Finechemicals Biopharmaceutical Manufacturing Technology Biopharmaceutical CDMO Small Molecule Drugs CDMO < 和光純薬 > Chemical 免疫分析装置 Synthesis Technology 生化学分析試薬国内の営業網 Cell Culture Medium Manufacturing Technology Vast Sales Network to Capture Client Needs Expanding Pharmaceutical CDMO business 11

13 Highly Functional Materials (Electronic Materials Business) Photoresist CMP Slurry Materials for Image Sensor, etc. < 和光純薬 > 免疫分析装置生化学分析試薬国内の営業網 High Purity Cleaning Agent High Quality Etching Solution Non-Ionic Surfactants, etc. Wafer (face down) Load CMP Slurry Polishing Pad Rotating Head Rotating Plate CMP Process Accelerating Electronic Materials Business 12

14 Highly Functional Materials Synergy (Industrial Products Business) Chemical Synthesis Technology Analysis Technology Library of 200,000 chemical compounds Strong Global Business Platform < 和光純薬和光純薬 > 重合開始剤等免疫分析装置 Polymerization 生化学分析試薬 Initiator 国内の営業網 Vast Polymeric Material Domestic and Global Speciality Chemical Manufacturing Sites Expanding Speciality Chemicals Business Globally 13

15 Overview of Acquisition Acquisition Structure: Tender Offer Price: Tender Offer for shares of Wako Pure Chemical Industries, Ltd. by FUJIFILM Corporation JPY 8,535 per share Expected Amount of Funds Necessary for Tender Offer: Approximately JPY154.7 billion Expected Schedule: Feb.27 Apr.3 Apr.21 Tender offer period for Wako shares Settlement of Tender Offer (consolidation of Wako) In the event of successful completion of the Tender Offer, Wako will be a consolidated subsidiary of Fujifilm Holdings on Apr. 21, Therefore, we expect no impact on Fujifilm Holdings FY2017/3 consolidated financial results. We will announce the impact for FY2018/3 consolidated financial results once details are confirmed. 14

16 Revenue Target of Wako Pure Chemical After Acquisition To Achieve JPY 100billion in Revenue by FY2022/3 Further Growth (JPY bn) Specialty Chemicals Clinical Diagnostics Reagents Laboratory Chemicals 15

17

Innovating out of Crisis

Innovating out of Crisis Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab

More information

Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical

Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings

More information

Nomura Investment Forum 2012

Nomura Investment Forum 2012 Shigetaka Komori Chairman, Representative Director and CEO December 4, 2012 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings forecasts and other projections contained

More information

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,

More information

Outline of the Business Alliance

Outline of the Business Alliance Notification with Respect to the Basic Agreement Between FUJIFILM Holdings Corporation, Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. Regarding a Strategic Capital and Business Alliance

More information

Tsumura to Hold Presentation on Vision for Business in China

Tsumura to Hold Presentation on Vision for Business in China NEWS RELEASE Name of Listed Company Representative Contact TSUMURA & CO. Terukazu Kato President & Representative Director February 14, 2018 (Code: 4540 First Section of the Tokyo Stock Exchange) Noboru

More information

Konica Minolta to Acquire Ambry Genetics (US)

Konica Minolta to Acquire Ambry Genetics (US) Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine

More information

Fujifilm s Initiatives in Regenerative Medicine

Fujifilm s Initiatives in Regenerative Medicine Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business

More information

About the Fujifilm Group 2. Management Message 16. Message from the CEO 16 Interview with the COO 20. Corporate Governance 24. Business Activities 36

About the Fujifilm Group 2. Management Message 16. Message from the CEO 16 Interview with the COO 20. Corporate Governance 24. Business Activities 36 CONTENTS About the Fujifilm Group 2 Value Creation Process 3 The Fujifilm Group s Value Creation History 4 Business Portfolio and Competitive Advantages 6 Financial Highlights 8 New CSR Plan / New Medium-Term

More information

A Shimadzu Brand with a Committed Worldwide Client Base

A Shimadzu Brand with a Committed Worldwide Client Base Outline of the New Medium-Term Management Plan (2008 2010) A Shimadzu Brand with a Committed Worldwide Client Base Towards a Truly Global Business March 24, 2008 Hattori Shigehiko President and CEO 1 I.

More information

Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA

Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical

More information

FUJIFILM Holdings to own 50.1% of Xerox Corporation s shares, and the combination of Fuji Xerox and Xerox Corporation

FUJIFILM Holdings to own 50.1% of Xerox Corporation s shares, and the combination of Fuji Xerox and Xerox Corporation FUJIFILM Holdings to own 50.1% of Xerox Corporation s shares, and the combination of Fuji Xerox and Xerox Corporation Shigetaka Komori Chairman and CEO, FUJIFILM Holdings Corporation January 31, 2018 FORWARD-LOOKING

More information

Presentation for IR Meeting

Presentation for IR Meeting Q1 FY2018 - Apr 1, 2018 to Jun 30, 2018 - Presentation for IR Meeting July 31, 2018 Key points of the first quarter of fiscal 2017 In the 1Q (April to June) of FY2018 sales and operating profit increased

More information

BD Strategy Overview. Advancing the world of health. Vincent A. Forlenza Chairman, Chief Executive Officer and President

BD Strategy Overview. Advancing the world of health. Vincent A. Forlenza Chairman, Chief Executive Officer and President BD Strategy Overview Advancing the world of health Vincent A. Forlenza Chairman, Chief Executive Officer and President BD IS AT THE VERY BEGINNING OF AN AMAZING JOURNEY WHERE WE CAN HAVE A PROFOUND IMPACT

More information

Fujifilm Group - Business Overview

Fujifilm Group - Business Overview Fujifilm Group - Business Overview Nov. 2017 FORWARD-LOOKING STATEMENTS Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management

More information

Earnings of FY2018/3 3Q

Earnings of FY2018/3 3Q Earnings of Jan. 31, 2018 FORWARD-LOOKING STATEMENTS Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management s current

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

YY/T INDUSTRY STANDARD OF THE PEOPLE S REPUBLIC OF CHINA

YY/T INDUSTRY STANDARD OF THE PEOPLE S REPUBLIC OF CHINA Translated English of Chinese Standard: YY/T1176-2010 Translated by: www.chinesestandard.net Wayne Zheng et al. Email: Sales@ChineseStandard.net ICS 11.100 YY C 44 INDUSTRY STANDARD OF THE PEOPLE S REPUBLIC

More information

Mitsubishi Chemical Holdings to Establish Life Science Institute, Inc.

Mitsubishi Chemical Holdings to Establish Life Science Institute, Inc. February 6, 2014 Mitsubishi Chemical Holdings Corporation Mitsubishi Chemical Holdings to Establish Life Science Institute, Inc. Mitsubishi Chemical Holdings Corporation (MCHC; Chiyoda-ku, Tokyo; Yoshimitsu

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference 34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements

More information

High Performance Plastics (HPP) Company

High Performance Plastics (HPP) Company Sekisui Chemical Integrated Report 217 25 High Performance Plastics (HPP) Company Business Overview The s strengths are its original fine particle, adhesion, precise synthesis, and other technologies upon

More information

Creating Corporate Value

Creating Corporate Value Revenue Breakdown by Business Segment Fine Chemicals and Other Products Business 37.1% Elastomers 49.2% Plastics 13.7% Petrochemical Products Business Creating Corporate Value The three strategic domains

More information

UK & Japanese Biomedical Engineering Collaborations. Anil Vaidya Life Science Specialist, JETRO

UK & Japanese Biomedical Engineering Collaborations. Anil Vaidya Life Science Specialist, JETRO UK & Japanese Biomedical Engineering s Anil Vaidya Life Science Specialist, JETRO Japan Land of Innovative Engineering Yamaha s Motorcycling Robot Toshiba Developing Vegetable Factories Maglev Train to

More information

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP

More information

Thanks, Bill. Good morning, everyone, and thanks for joining us.

Thanks, Bill. Good morning, everyone, and thanks for joining us. Cabot Microelectronics Corporation 2007 Third Fiscal Quarter Earnings Report July 26, 2007 Good morning. This is Bill Johnson, Vice President and Chief Financial Officer for Cabot Microelectronics Corporation.

More information

Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion

Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes

More information

China s Strategic Emerging Industries and Their Potential Impacts on MNCs

China s Strategic Emerging Industries and Their Potential Impacts on MNCs China s Strategic Emerging Industries and Their Potential Impacts on MNCs Benjamin Bai Partner Allen & Overy LLP January 2013 Allen & Overy 2013 Allen & Overy 2013 South China Morning Post, August 28,

More information

Creating, Saving and Storing. Fast, Fine and Beautiful. Telecommunications. Environment & Energy. Main Products Circuit Connecting Films for Displays

Creating, Saving and Storing. Fast, Fine and Beautiful. Telecommunications. Environment & Energy. Main Products Circuit Connecting Films for Displays Focused Business Fields Focused Business Fields Creating, Saving and Storing Fast, Fine and Beautiful Telecommunications Environment & Energy Through state-of-the-art technology development for materials

More information

Overview of the current Japanese biotech industry and investment outlook

Overview of the current Japanese biotech industry and investment outlook Overview of the current Japanese biotech industry and investment outlook Daiwa SMBC Capital Co.,Ltd Hiroki Narita Deputy General Manager E-mail:narita@daiwasmbc-cap.co.jp Biotechnology Market in Japan

More information

Cyclic Innovation for Clinical Empowerment. (CiCLE)

Cyclic Innovation for Clinical Empowerment. (CiCLE) Cyclic Innovation for Clinical Empowerment (CiCLE) Japan Agency for Medical Research and Development (AMED), National Research and Development Agency 1 Cyclic Innovation for Clinical Empowerment (CiCLE)

More information

Corporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation

Corporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation May 16, 2007 Press Release Tanabe Seiyaku Co., Ltd. Mitsubishi Pharma Corporation Corporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation

More information

Realizing the Future that Regenerative Medicine Will Open

Realizing the Future that Regenerative Medicine Will Open 470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine

More information

Acquisition of COSMOTEC

Acquisition of COSMOTEC Acquisition of COSMOTEC Reference Material September 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking

More information

Building the Europe of Knowledge

Building the Europe of Knowledge Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:

More information

Full Acquisition of Yusen Logistics Co., Ltd.

Full Acquisition of Yusen Logistics Co., Ltd. Full Acquisition of Logistics Co., Ltd. October 31, 2017 2016. NYK Group. All rights 2016. reserved. NYK Group. All rights reserved. Transaction Overview Overview Nippon s full acquisition of Logistics

More information

Jefferies 2018 Global Healthcare Conference. June 7, 2018

Jefferies 2018 Global Healthcare Conference. June 7, 2018 Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business

More information

Evonik Birmingham Laboratories

Evonik Birmingham Laboratories Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories

More information

MELISSA STAHL RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY

MELISSA STAHL RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY TECHNOLOGY INTEGRATION AT LEADING HEALTH SYSTEMS VENDOR NEUTRAL ARCHIVES AT INDIANA UNIVERSITY HEALTH MELISSA STAHL RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY The Academy The Health Management Academy

More information

Clinical Supply Packaging for Biological Products

Clinical Supply Packaging for Biological Products Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply

More information

Scientific Solutions Business Strategy

Scientific Solutions Business Strategy Scientific Solutions Business Strategy Toshihiko Okubo Division Manager Scientific Solutions Business Strategy Division Olympus Corporation March 30, 2016 Todayʼs Agenda 1.Business Overview 2.Recognition

More information

Execution Status of Law concerning the Evaluation and Regulation of Manufacture, etc. of Chemical Substances (CSCL) (2006)

Execution Status of Law concerning the Evaluation and Regulation of Manufacture, etc. of Chemical Substances (CSCL) (2006) Execution Status of Law concerning the Evaluation and Regulation of Manufacture, etc. of Chemical Substances (CSCL) (2006) July 20, 2007 Chemical Safety Office, Chemical Management Policy Division, Manufacturing

More information

Basic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.

Basic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications. APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,

More information

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External

More information

Urban Infrastructure & Environmental Products (UIEP) Company

Urban Infrastructure & Environmental Products (UIEP) Company Sekisui Chemical Integrated Report 218 President s Policy Get on the track for Growth Expanding business Field with Competitive Technology and Products 1. Expand Sales of Growth Products by Concentrating

More information

Welcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese

More information

Financial Results for FY2017 and Strategy

Financial Results for FY2017 and Strategy Financial Results for FY2017 and Strategy Recruit Holdings Co., Ltd. Masumi Minegishi President, CEO, and Representative Director Keiichi Sagawa CFO and Senior Managing Corporate Executive Officer May

More information

YY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Total Prostate Specific Antigen (t-psa) Quantitative

YY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Total Prostate Specific Antigen (t-psa) Quantitative ICS 11.100 C 44 PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准 Total Prostate Specific Antigen (t-psa) Quantitative Detection Reagent (Kit) (Chemiluminescent Immimoassay) 总前列腺特异性抗原

More information

Company presentation Full year 2016

Company presentation Full year 2016 Company presentation Full year 2016 SOL Group at a glance Founded in 1927, is an Italian based multinational company present in 28 countries with more of 3,200 people employed. Two core, separated but

More information

NEW ERA OF A HYDROGEN ENERGY SOCIETY

NEW ERA OF A HYDROGEN ENERGY SOCIETY METI NEW ERA OF A HYDROGEN ENERGY SOCIETY October 19, 2015 Energy Conservation and Renewable Energy Department Director, and Fuel Cell Promotion Office Chihiro Tobe Dissemination of the Use of Energy Past

More information

A full-service CRO with integrated early-stage capabilities

A full-service CRO with integrated early-stage capabilities CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March

More information

China Diagnostic Reagent Industry Report, Nov. 2013

China Diagnostic Reagent Industry Report, Nov. 2013 China Diagnostic Reagent Industry Report, 2013-2015 Nov. 2013 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

Midterm Management Plan

Midterm Management Plan Midterm Management Plan From FY 2014 to FY 2016 Become an Innovative Company Contributing to Growth of Global Customers 2014.3.26 Shimadzu Corporation Akira Nakamoto, President and Chief Executive Officer

More information

33.8% Revenue Breakdown by Business Segment. Elastomers 51.6% Plastics 14.6% Petrochemical Products Business JSR CORPORATION ANNUAL REPORT 2014

33.8% Revenue Breakdown by Business Segment. Elastomers 51.6% Plastics 14.6% Petrochemical Products Business JSR CORPORATION ANNUAL REPORT 2014 > The JSR Group s objective is to secure stable earnings from the Petrochemical Products Business (Elastomers and ) and Fine Chemicals business and increase future profitability by positioning the

More information

Life Sciences Debashis Ghosh. 1 Copyright 2016 Tata Consultancy Services Limited

Life Sciences Debashis Ghosh. 1 Copyright 2016 Tata Consultancy Services Limited Life Sciences Debashis Ghosh 1 Copyright 2016 Tata Consultancy Services Limited From biology, chemistry and anatomy to data, analytics and technology Analytics driven Genomics Research We identify disease

More information

Mitsubishi Chemical Group KAKUSHIN-Phase1

Mitsubishi Chemical Group KAKUSHIN-Phase1 Mitsubishi Chemical Group KAKUSHIN-Phase1 November 14, 2002 1.. Management Issues and Policies 2. Gist of KAKUSHIN - Phase 1 1 Plan (1) Portfolio Reform (2) Improvement of Financial Position (3) R&TD Policy

More information

YY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Automatic Luminescence Immunoassay Analyzer 全自动发光免疫分析仪

YY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Automatic Luminescence Immunoassay Analyzer 全自动发光免疫分析仪 ICS 11.100 C 44 PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准 Automatic Luminescence Immunoassay Analyzer 全自动发光免疫分析仪 Issued on December 30, 2009 Implemented on June 1, 2011 Issued

More information

Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Company Profile. German-Taiwan Biotech Seminar 6 November 2017 Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical

More information

Wind Farm Technologies

Wind Farm Technologies Wind Farm Technologies Dr. LIU Yongqian Professor, Renewable Energy School North China Electric Power University No.2 BeiNong Road, HuiLongGuan, ChangPing, Beijing, 102206 China Email: yqliu@ncepu.edu.cn

More information

Progenika Biopharma Group

Progenika Biopharma Group Progenika Biopharma Group Foro del emprendedor BCN2011 5 Septiembre 2011 Progenika Biopharma Pioneering Personalized Medicine Progenika, leading company in Personalized Medicine Progenika is a leading

More information

1.Bioinstrumentation *SIMPLE AND QUICK GENETIC TESTING DEVICES (INFECTION & OTHERS, ON MARKET<OM> IN JAPAN)

1.Bioinstrumentation *SIMPLE AND QUICK GENETIC TESTING DEVICES (INFECTION & OTHERS, ON MARKET<OM> IN JAPAN) R & D, Commercialization projects 1.Bioinstrumentation *SIMPLE AND QUICK GENETIC TESTING DEVICES (INFECTION & OTHERS, ON MARKET IN JAPAN) *DOWNSIZED SYSTEM FOR MEASURING RESPIRATORY SYSTEM IMPEDANCE

More information

Global and China Biopharmaceutical Industry Report, 2010

Global and China Biopharmaceutical Industry Report, 2010 Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound

More information

May 14, 2014 CGI Announces Acquisition of BioServe India

May 14, 2014 CGI Announces Acquisition of BioServe India Empowering Personalized Cancer Treatment May 14, 2014 CGI Announces Acquisition of BioServe India CGI and BioServe India Enter Into Acquisition Agreement On May 14 th, 2014 Cancer Genetics, Inc. and BioServe

More information

We work with passion, using advanced technologies, to transform life science into new possibilities for our customers

We work with passion, using advanced technologies, to transform life science into new possibilities for our customers We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Business Update: First Quarter 2009 23 April 2009 Stefan Borgas Chief Executive Officer

More information

6. Vision 3: Leading the Japanese economy forward as a high value-added industry"

6. Vision 3: Leading the Japanese economy forward as a high value-added industry 6. Vision 3: Leading the Japanese economy forward as a high value-added industry" Strategic points for realizing the vision Streamlining and rationalization R&D to create innovative drugs Proactively introducing

More information

Creative Hybrid Chemistry For a Better Tomorrow

Creative Hybrid Chemistry For a Better Tomorrow Creative Hybrid Chemistry For a Better Tomorrow December 12, 2011 Masakazu Tokura President Agenda Overview of FY2011 Performance 2 Sumitomo Chemical s Current Position 6 Review of Major Strategic Initiatives

More information

Gap Analysis for Drug Development Process

Gap Analysis for Drug Development Process Gap Analysis for Drug Process Dr. Jia Ming Chang AM4 Preclinical Animal Testing Center Institute for Drug Evaluation Platform Center for Biotechnology Benefit of Gap Analysis Gap analysis service support

More information

Human ips/es Cell Technology and Its Application to Toxicology Testing

Human ips/es Cell Technology and Its Application to Toxicology Testing Human ips/es Cell Technology and Its Application to Toxicology Testing -Especially focusing on in vitro cardiac function toxicity- Atsushi Sanbuissho, PhD Daiichi Sankyo Co., Ltd. Kenji Yasuda, Prof Tokyo

More information

To meet the challenge of providing safe, cost-effective medicines for the world s largest

To meet the challenge of providing safe, cost-effective medicines for the world s largest An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China

More information

Getting to the Factory of the Future

Getting to the Factory of the Future Patient-Specific Cell Therapy Getting to the Factory of the Future Robert A. Preti, PhD Chief Executive Officer and President, PCT General Manager, Global Regenerative Medicine Business Sector, Hitachi

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

MediSapiens Ltd. Because data is not knowledge. 4th of November Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd

MediSapiens Ltd. Because data is not knowledge. 4th of November Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd 4th of November 2014 MediSapiens Ltd Because data is not knowledge Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2014 MediSapiens Ltd. All rights reserved. medisapiens.com MediSapiens Brief

More information

Patenting biotechnological inventions

Patenting biotechnological inventions Patenting biotechnological inventions Izabela Milczarek, PhD, Specialist in Patents Department at Patpol Patpol - European and Polish Patent and Trade Mark Attorneys What is biotechnology? The 20 th century

More information

Business Update: First Quarter 2007

Business Update: First Quarter 2007 Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements

More information

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. YY/T Translated English of Chinese Standard: YY/T

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. YY/T Translated English of Chinese Standard: YY/T Translated English of Chinese Standard: www.chinesestandard.net Buy True-PDF Auto-delivery. Sales@ChineseStandard.net PHARMACEUTICAL INDUSTRY STANDARD YY OF THE PEOPLE S REPUBLIC OF CHINA ICS 11.100 C

More information

The main goal of the strategic partnership is the development of innovative, all-natural cosmetic active ingredients and aroma molecules.

The main goal of the strategic partnership is the development of innovative, all-natural cosmetic active ingredients and aroma molecules. PRESS RELEASE Symrise: Strategic partnership with BRAIN and AnalytiCon Discovery (Holzminden/Potsdam/Zwingenberg, April 2, 2007) Symrise GmbH & Co. KG, the world s fourth-largest supplier of fragrance

More information

Conference Exhibitors

Conference Exhibitors Conference Exhibitors CSM Executive and the 2018 Manitoba Local Organizing Committee would like to thank the following organizations for exhibiting and supporting the Canadian Society of Microbiologists

More information

Real solutions for real-world problems.

Real solutions for real-world problems. Digital Health Real solutions for real-world problems. Today, it costs around $2.6 billion and takes between 10 and 15 years to develop a new drug. 1 Despite the enormity of this investment, once the drug

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

Creating Corporate Value

Creating Corporate Value 11 Creating Corporate Value Bioprocess Display The three strategic domains for JSR Group are petrochemical products, fine chemicals, and life sciences. In each of these areas, we are developing business

More information

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS

More information

Jefferies 2015 Global Healthcare Conference June 3, 2015

Jefferies 2015 Global Healthcare Conference June 3, 2015 Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act

More information

Masaki Muto MD PhD Chairman, Japan Society of Generic Medicines (Professor, International University of Health and Welfare Graduate School )

Masaki Muto MD PhD Chairman, Japan Society of Generic Medicines (Professor, International University of Health and Welfare Graduate School ) Masaki Muto MD PhD Chairman, Japan Society of Generic Medicines (Professor, International University of Health and Welfare Graduate School ) Agenda Part 1 Current Status of Generics Market in Japan Part

More information

We make drugs smarter

We make drugs smarter We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities

More information

Sources: Tokyo Institute of Technology City of Kawasaki. For immediate release: August 4, 2017

Sources: Tokyo Institute of Technology City of Kawasaki. For immediate release: August 4, 2017 PRESS RELEASE Sources: Tokyo Institute of Technology City of Kawasaki For immediate release: August 4, 2017 Subject line: Tokyo Institute of Technology and Kawasaki City are Combining Forces in R&D on

More information

Almac Overview.

Almac Overview. Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide

More information

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of

More information

CMP MARKETS & VALUE CHAIN PERSPECTIVES

CMP MARKETS & VALUE CHAIN PERSPECTIVES CMP MARKETS & VALUE CHAIN PERSPECTIVES MICHAEL CORBETT MANAGING PARTNER LINX CONSULTING MCORBETT@LINX-CONSULTING.COM A PRESENTATION FOR THE CMP USERS GROUP JULY 17, 2007 LINX CONSULTING OUTLINE 1. Introduction

More information

Financial Results for the Fiscal Year Ended March 31, April 27, 2018 NEC Corporation (https://www.nec.com/en/global/ir)

Financial Results for the Fiscal Year Ended March 31, April 27, 2018 NEC Corporation (https://www.nec.com/en/global/ir) Financial Results for the Fiscal Year Ended March 31, 2018 April 27, 2018 NEC Corporation (https://www.nec.com/en/global/ir) Index Ⅰ. Financial Results for Ⅱ. Financial Forecasts for FY19/3 Ⅲ. Progress

More information

BEYOND 300 (FY FY2020)

BEYOND 300 (FY FY2020) Mid-term Management Plan BEYOND 300 (FY2018 - FY2020) ADEKA Corporation Stock Code: 4401 1 Table of Contents 1. Review of STEP 3000-II Overview Financial Performance Management Indexes Summary 2. ADEKA

More information

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low

More information

M3, Inc. Presentation Material. July Copyright 2017 M3, Inc. All rights reserved.

M3, Inc. Presentation Material. July Copyright 2017 M3, Inc. All rights reserved. M3, Inc. Presentation Material July 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking projections

More information

For Early Access of Innovative Medical Devices to Patients

For Early Access of Innovative Medical Devices to Patients Summit of Heads of Medicines Regulatory Agencies Symposium For Early Access of Innovative Medical Devices to Patients October 27 th, 2017 Masaya Watanabe Chairman, The Japan Federation of Medical Devices

More information

FY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda

FY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda FY2017 to FY2019 Medium-Term Management Plan March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda Contents I. Review of the Previous Plan p.1-4 II. Overview of the New Medium-Term Management

More information

New strategic initiative at Wacom Shift focus to profitability, grow corporate value in the medium term

New strategic initiative at Wacom Shift focus to profitability, grow corporate value in the medium term For reference (*) March 14, 2017 New strategic initiative at Wacom Shift focus to profitability, grow corporate value in the medium term 1. Background In April 2015, Wacom unveiled its Strategic Business

More information

Presentation to Investors. February, 2003

Presentation to Investors. February, 2003 Presentation to Investors February, 2003 Table of Contents 1. Review of Latest Performance 2. KAKUSHIN Plan Appendix Forward-Looking Statements: This material contains forward-looking statements which

More information

Pfizer Completes Acquisition of Hospira

Pfizer Completes Acquisition of Hospira For immediate release: September 3, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Chuck Triano (212) 733-3901 Pfizer Completes Acquisition of Hospira Creates a leading Global Established

More information

In the Midst of Changing Times Revolutionary Technology and Products Driving Corporate Evolution

In the Midst of Changing Times Revolutionary Technology and Products Driving Corporate Evolution The Story of Sumitomo Chemical Trajectory Since Its Founding In the Midst of Changing Times Revolutionary Technology and Products Driving Corporate Evolution 1915-1945- Building a Foundation as a Chemical

More information

The Microsoft Conference 2014 ROOM F

The Microsoft Conference 2014 ROOM F The Microsoft Conference 2014 ROOM F 既存社内システムの問題点と対策 Dynamics AX とは? マイクロソフト製品との広範囲な相互運用性を持つ柔軟性の高い操作性を重視したグローバル ERP 同一製品内で複数の業種機能に対応可能 36 ヵ国の税法 41 言語 複数通貨を 1 導入で実現 柔軟なカスタマイズを可能にする統合開発環境と階層構造 AX クライアントによるシンプルな操作性と

More information

Gene Techno Science Co., Ltd.

Gene Techno Science Co., Ltd. Unlimited drug discovery from the beginning Ticker symbol: 4584 Gene Techno Science Co., Ltd. Financial Results for the Fiscal Year Ended March 2018 May 16, 2018 1 2 Corporate overview Chief Executive

More information